NOTE: Although this activity is no longer certified for credit, we believe that it contains important information and hope you’ll review, print or email it to a colleague.
Personalizing the Initial Therapy of Advanced Non-Small-Cell Lung Cancer (NSCLC)
1.00 AMA PRA Category 1 Credits
Identify 2 ways in which pathologic features of a tumor in an individual with advanced NSCLC affect the outcome produced by a particular chemotherapeutic regimen, and apply this information to the choice of initial systemic therapy for these patients in daily practice.
Essential Areas and Policies, including the 2004 Updated Standards for Commercial Support. Pri-Med faculty hail from a variety of institutions and participate in content development, along with Pri-Med Institute's Advisory Boards and its expert review partners, the University of Wisconsin School of Medicine and Public Health and Tufts Health Care Institute. All final decisions about program content are the responsibility of Pri-Med Institute.
||AMA PRA Category 1 Credits
||Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
||Pri-Med Institute designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Faculty and Editorial Board
Mark G. Kris, MD, (Read Bio), Professor of Medicine, Weill-Cornell Medical College, Chief, Thoracic Oncology Service; William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan-Kettering Cancer Center
Kate Rouhana, Pri-Med Institute
Financial Disclosure Statement(s)
Dr Kris serves as a consultant for Bristol-Myers Squibb, ImClone, and AstraZeneca.
The content collaborators at Dana-Farber Cancer Institute have no financial relationships to disclose.
Ms Rouhana has no financial relationships to disclose.
Dana-Farber Cancer Institute
Lilly, USA, LLC, Genentech BioOncology and OSI Oncology, and Bristol-Myers Squibb & ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company
Instructions for Obtaining Credit:
Complete this activity. Answer the questions in the attached posttest and evaluation. Click on "claim credit" and follow the instructions to print out the credit certificate.
Computer System Requirements:
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, M|C Communications, LLC, or the Dana-Farber Cancer Institute.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.